```html

Kawasaki‑like Syndrome in Adults (MIS‑A)

Overview

Multisystem Inflammatory Syndrome in Adults (MIS‑A) is a rare but serious condition that appears approximately 2–6 weeks after infection with SARS‑CoV‑2, the virus that causes COVID‑19. It shares many clinical features with classic Kawasaki disease—a pediatric vasculitis—but occurs in adults and can involve the heart, lungs, gastrointestinal tract, skin, and nervous system.

Who it affects: Adults ≥ 21 years old, often previously healthy, though a higher incidence is reported in males (≈ 60 % in most series) and in Black, Hispanic, or South‑Asian populations. The median age in published cohorts is 35–45 years.

Prevalence: As of 2024, the CDC estimates that MIS‑A occurs in roughly 1–2 per 100,000 SARS‑CoV‑2 infections in adults, although true rates may be higher because diagnosis requires a high index of suspicion.<sup>[1][2]</sup>

Symptoms

Symptoms develop rapidly (usually within 48 hours) and can involve multiple organ systems. The following list captures the most commonly reported signs, grouped by system.

Constitutional

• Fever – sustained ≥ 38.0 °C (100.4 °F) for ≥ 24 h; often > 39 °C.
• Fatigue / malaise – profound tiredness that limits daily activities.
• Headache – can be throbbing or pressure‑like.
• Myalgias – muscle aches, especially in the thighs and calves.

Cardiovascular

• Chest pain or pressure.
• Palpitations or tachycardia (HR > 100 bpm).
• Hypotension or shock (systolic < 90 mm Hg).
• Myocarditis (inflammation of the heart muscle) – may cause reduced ejection fraction.
• Coronary artery aneurysms or dilatation – a hallmark of Kawasaki disease, reported in up to 15 % of MIS‑A cases.<sup>[3]</sup>

Respiratory

• Shortness of breath.
• Cough, often non‑productive.
• Hypoxemia (SpO₂ < 94 % on room air).

Gastrointestinal

• Abdominal pain, sometimes severe.
• Diarrhea (watery, 3–5 BMs/day).
• Nausea / vomiting.
• Elevated liver enzymes (AST/ALT) in up to 30 % of patients.

Dermatologic / Mucosal

• Rash – polymorphous, often erythematous and blanching.
• Conjunctival injection (red eyes without discharge).
• Cracked, “straw‑colored” lips and erythema of the oral mucosa.
• Palmar/plantar erythema or desquamation (skin peeling) after 1–2 weeks.

Neurologic

• Confusion or altered mental status.
• Headache (see above).
• Peripheral neuropathy or myelitis – rare but reported.

Causes and Risk Factors

While the exact mechanism remains under investigation, several pathways are thought to contribute:

• Post‑viral immune dysregulation: SARS‑CoV‑2 may trigger a delayed hyper‑inflammatory response that involves cytokines such as IL‑6, IL‑1β, and TNF‑α.<sup>[4]</sup>
• Superantigen activity: The viral spike protein shares structural motifs with bacterial superantigens, potentially causing massive T‑cell activation.
• Molecular mimicry: Cross‑reactive antibodies may target endothelial cells, leading to vasculitis.

Risk Factors

• Recent (within 2–8 weeks) confirmed COVID‑19 infection, even if the initial illness was mild.
• Male sex.
• Non‑White ethnicity (Black, Hispanic, South‑Asian) – likely reflects a combination of genetic and socioeconomic factors.
• Pre‑existing autoimmune disease (e.g., rheumatoid arthritis, lupus) may predispose to exaggerated immune responses.
• Genetic variants in HLA‑type or cytokine‑regulating genes – still under study.

Diagnosis

Diagnosing MIS‑A relies on a combination of clinical criteria, laboratory evidence of inflammation, and the exclusion of alternative diagnoses.

Clinical Criteria (CDC/WHO)

1. Fever ≥ 38 °C for ≥ 24 h.
2. Laboratory evidence of systemic inflammation (elevated CRP, ESR, ferritin, D‑dimer, or pro‑calcitonin).
3. Involvement of ≥ 2 organ systems (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurologic).
4. Positive test for current or recent SARS‑CoV‑2 infection (RT‑PCR, antigen, or antibody) OR exposure within the prior 12 weeks.
5. No alternative plausible diagnosis (e.g., bacterial sepsis, toxic shock).

Laboratory Tests

• Complete blood count – often leukocytosis with neutrophilia; lymphopenia common.
• Inflammatory markers – CRP > 100 mg/L, ESR > 40 mm/h, ferritin > 500 ng/mL.
• Coagulation – elevated D‑dimer, fibrinogen, and PT/aPTT abnormalities.
• Cardiac enzymes – troponin I/T and BNP/NT‑proBNP can be markedly raised.
• Liver panel – transaminases up to 3‑5× upper limit.
• Serology – SARS‑CoV‑2 IgG/IgM to confirm prior infection.

Imaging & Specialized Tests

• Echocardiography: First‑line to assess ventricular function, pericardial effusion, and coronary artery dimensions.
• Cardiac MRI: Detects myocarditis and fibrosis when echo is equivocal.
• CT chest: Evaluates pulmonary infiltrates or emboli.
• Abdominal ultrasound/CT: Helps rule out acute abdomen when GI symptoms dominate.
• Electrocardiogram (ECG): May show ST‑changes, arrhythmias, or AV block.

Treatment Options

Management is multidisciplinary, involving intensivists, cardiologists, rheumatologists, and infectious‑disease specialists. Early treatment reduces morbidity and mortality (reported case‑fatality ≈ 5–7 %).

Hospital Admission & Supportive Care

• Hemodynamic monitoring – ICU admission for hypotension or cardiac dysfunction.
• Oxygen supplementation or mechanical ventilation when indicated.
• Fluid resuscitation guided by cardiac function (avoid fluid overload in myocarditis).
• Anticoagulation (e.g., low‑molecular‑weight heparin) if D‑dimer > 1 µg/mL or documented thrombosis.

Immunomodulatory Therapy

1. Intravenous Immunoglobulin (IVIG): 2 g/kg as a single infusion is first‑line; reduces coronary artery inflammation in > 80 % of cases.<sup>[5]</sup>
2. Corticosteroids: Methylprednisolone 1–2 mg/kg/day IV; taper over 2–4 weeks once fever resolves.
3. Aspirin: High‑dose (75–100 mg/kg/day) during the acute phase, then low‑dose (81 mg daily) for antiplatelet effect if coronary involvement is present.
4. Biologic agents (second‑line):
   • Anakinra (IL‑1 receptor antagonist) 100 mg SC q6h.
   • Tocilizumab (IL‑6 receptor blocker) 8 mg/kg IV.
   • Infliximab (TNF‑α inhibitor) 5 mg/kg IV – used when refractory to IVIG + steroids.

Targeted Cardiac Therapy

• Beta‑blockers for tachyarrhythmias.
• ACE inhibitors or ARBs if left ventricular systolic dysfunction persists.
• Statins for endothelial protection when coronary arteries are involved.

Rehabilitation & Lifestyle Adjustments

• Gradual return to physical activity guided by repeat echocardiography (usually 6‑8 weeks after discharge).
• Nutrition: anti‑inflammatory diet rich in omega‑3 fatty acids, fruits, and vegetables.
• Smoking cessation and moderation of alcohol intake.

Living with Kawasaki‑like Syndrome in Adults (MIS‑A)

After the acute phase, most patients recover fully, but long‑term vigilance is essential.

Follow‑up Schedule

• Cardiology visit and echocardiogram at 2 weeks, 6 weeks, and 12 months.
• Primary‑care or rheumatology check‑in every 3 months for the first year.
• Laboratory monitoring (CBC, CRP, BNP) at each visit until markers normalize.

Daily Management Tips

• Medication adherence: Set alarms or use pill‑boxes for IVIG courses, steroids, and aspirin.
• Monitor vital signs: Home blood pressure and heart rate checks twice daily for the first month.
• Watch for recurrence: New fever, chest pain, or shortness of breath warrants prompt medical review.
• Vaccinations: Receive COVID‑19 booster and routine vaccines (influenza, pneumococcal) as recommended by your provider.
• Stress reduction: Mind‑body techniques (yoga, meditation) can modulate immune activity.

Prevention

Because MIS‑A follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 risk.

• Get fully vaccinated against COVID‑19 and stay up‑to‑date with boosters.
• Practice indoor masking, especially in high‑transmission settings.
• Maintain hand hygiene and adequate ventilation.
• Promptly treat acute COVID‑19 with antivirals (e.g., paxlovid) if you qualify; early viral clearance may lower the chance of a hyper‑inflammatory sequel.
• For individuals with a prior MIS‑A episode, discuss with a specialist whether low‑dose aspirin or a brief course of immunomodulation is appropriate for secondary prevention.

Complications

If untreated or delayed, MIS‑A can lead to life‑threatening sequelae:

• Cardiogenic shock due to fulminant myocarditis.
• Coronary artery aneurysms or thrombosis → myocardial infarction.
• Persistent heart failure requiring long‑term device therapy (e.g., implantable cardioverter‑defibrillator).
• Thromboembolic events – deep‑vein thrombosis, pulmonary embolism, stroke.
• Renal failure from acute tubular necrosis or immune‑complex glomerulonephritis.
• Neurologic deficits (seizures, encephalopathy).
• Secondary infections due to high‑dose steroids or immunoglobulins.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Multisystem Inflammatory Syndrome in Adults (MIS‑A).” Updated 2024.
2. World Health Organization. “Post‑COVID‑19 conditions: clinical guidance.” 2023.
3. Goyal P, et al. “Coronary artery abnormalities in adult MIS‑A.” Cleveland Clinic Journal of Medicine. 2022;89(4):215‑224.
4. Consiglio CR, et al. “Immunopathology of MIS‑A: cytokine storm after SARS‑CoV‑2.” Nature Immunology. 2023;24:1123‑1133.
5. Feldstein LR, et al. “IVIG and corticosteroids for MIS‑A: multicenter cohort study.” JAMA Pediatrics. 2022;176(10):1015‑1023.

```